Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2003

View Archived Issues

Novel antibacterial DNA-binding agents presented by GeneSoft

New endothelin antagonists in early development at GSK

Merck researchers describe novel PTP1B inhibitors for diabetes and metabolic disorders

New antitumor daunorubicin derivatives designed by Pharmacia

Agouron claims new HIV protease inhibitors

Idec and Biogen to codevelop three Biogen oncology therapeutics

Elan agrees to sell primary care franchise to King

Biogen updates key product development

CuraGen reports progress in 2002

Phase I results for trastuzumab with IL-2 in nonhematological cancer

Clinical use of a humanized anti-IL-6R monoclonal antibody in rheumatoid arthritis

Gabapentin safe and effective in reducing pain of Guillain-Barre syndrome

Regeneron reports progress of Axokine and other programs

Recent developments at Seattle Genetics

Bayer and Aventis abandon plans for biologicals joint venture

NIH grant supports Cerebril trials

Enrollment completed in phase III Tarceva trial in refractory NSCLC

ALVAC-CEA/B7.1 under investigation in two colorectal cancer trials

NDA filing planned for PDT therapy for AMD

Marketing clearance sought for Estorra for insomnia

BioTransplant and Catholic University of Louvain attempt to resolve dispute regarding MEDI-507

First biologic therapy for psoriasis approved by FDA

Aventis identifies nonpeptide, orally active Ang-(1-7) agonist

Approval of micafungin in the U.S. may be delayed

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.